Clinical Trials Browser

Phase 2 × Has results × osimertinib × Clear all

NCT06303167 2026-03-19

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Phase 2 Active not recruiting

19 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Phase 2 Active not recruiting

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

Phase 2 Active not recruiting

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03778229 2026-02-10

SAVANNAH

Phase 2 Active not recruiting

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT02442349 2026-01-09

AURA17

Phase 2 Completed

171 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03414814 2025-02-11

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Phase 2 Completed

15 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT03433469 2025-01-31

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Phase 2 Active not recruiting

27 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02841579 2025-01-28

AZENT

Phase 2 Completed

22 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT02094261 2024-11-06

AURA2

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02759835 2024-06-07

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Phase 2 Completed

37 enrolled 23 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT03434418 2023-10-17

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Phase 2 Completed

17 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms